Division of Respiratory Medicine, Cardiovascular and Thoracic Department, AOU Città della Salute e della Scienza di Torino, 10126 Torino, Italy.
Medical Sciences Department, University of Turin, 10126 Torino, Italy.
Viruses. 2024 Aug 4;16(8):1251. doi: 10.3390/v16081251.
The QuantiFERON CMV (QCMV) test evaluates specific adaptive immune system activity against CMV by measuring IFN-γ released by activated CD8+ T lymphocytes. We aimed to evaluate the QCMV test as a predictive tool for CMV manifestations and acute or chronic lung allograft rejection (AR and CLAD) in lung transplant (LTx) patients. A total of 73 patients were divided into four groups based on donor and recipient (D/R) serology for CMV and QCMV assay: group A low-risk for CMV infection and disease (D-/R-); group B and C at intermediate-risk (R+), group B with non-reactive QCMV and group C with reactive QCMV; group D at high-risk (D+/R-). Group D patients experienced higher viral replication; no differences were observed among R+ patients of groups B and C. D+/R- patients had a higher number of AR events and group C presented a lower incidence of AR. Prevalence of CLAD at 24 months was higher in group B with a higher risk of CLAD development (OR 6.33). The QCMV test allows us to identify R+ non-reactive QCMV population as the most exposed to onset of CLAD. This population had a higher, although non-significant, susceptibility to AR compared to the R+ population with reactive QCMV.
QuantiFERON CMV（QCMV）检测通过测量活化的 CD8+T 淋巴细胞释放的 IFN-γ，评估针对 CMV 的特定适应性免疫系统活性。我们旨在评估 QCMV 检测作为肺移植（LTx）患者 CMV 表现以及急性或慢性肺移植物排斥（AR 和 CLAD）的预测工具。共有 73 名患者根据 CMV 的供体和受体（D/R）血清学和 QCMV 检测结果分为四组：A 组为 CMV 感染和疾病低风险（D-/R-）；B 组和 C 组为中风险（R+），B 组 QCMV 无反应，C 组 QCMV 有反应；D 组为高风险（D+/R-）。D 组患者的病毒复制水平更高；B 组和 C 组的 R+患者之间没有观察到差异。D+/R-患者的 AR 事件更多，C 组的 AR 发生率较低。B 组 24 个月时 CLAD 的患病率更高，发展为 CLAD 的风险更高（OR 6.33）。QCMV 检测可识别 R+无反应 QCMV 人群，该人群发生 CLAD 的风险最高。与 R+有反应 QCMV 人群相比，该人群的 AR 易感性虽然没有统计学意义，但更高。
